2 unknown, 1 approved for marketing, 1 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Ming Zhao: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC Tislelizumab, Ablation - Recurrent Hepatocellular Carcinoma | Phase 2 | Unknown | Ming Zhao | 120 | 2020-12-21 | 2023-03-22 |
| TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma TACE, RFA - Hepatocellular Carcinoma, Chemoembolization, Therapeutic | Phase 3 | Completed | Ming Zhao | 241 | 2015-05-01 | 2026-03-31 |
| Combine TACE and RFA Versus TACE Alone for HCC With PVTT TACE, RFA, pirarubicin,mitomycin and lobaplatin - Hepatocellular Carcinoma | Phase 3 | Unknown | Ming Zhao | 240 | 2014-10-01 | 2016-04-14 |
| HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC HAIC using oxaliplatin plus fluorouracil/leucovorin, Oxaliplatin, Fluorouracil - Hepatocellular Carcinoma, Injury; Blood Vessel, Hepatic, Artery | Approved for marketing | Ming Zhao | 2019-08-20 |
Carcinoma, Hepatocellular (4) · Wounds and Injuries (1)
Chemoembolization, Therapeutic (1) · Cytotoxins (1) · Fluorouracil (1) · Leucovorin (1) · Mitomycin (1) · Oxaliplatin (1) · lobaplatin (1) · pirarubicin (1) · tislelizumab (1)
China (4)